A Study In Patients With Advanced Solid Tumor

A Phase 1 Study In Patients With Advanced Solid Tumor To Evaluate The Pharmacokinetics And Safety Of AG-013736 At Single Doses Of 5 mg, 7 mg And 10 mg, And At Multiple Doses

This study designed to evaluate the pharmacokinetics and safety of AG-013736 at single doses and multiple doses

Inclusion Criteria:

• Patients histologically or cytologically diagnosed with advanced solid tumors
• Patients for whom standard therapies have not been effective, or for whom there are no suitable therapies
• Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0, 1 or 2
• Patients with no uncontrolled hypertension

Exclusion Criteria:

• Patients who have central lung lesions involving major blood vessels
• Patients who require anticoagulant therapy.
• Patients with active epilepsy seizure or symptoms, with brain metastases requiring treatment, with spinal cord compression and with carcinomatous meningitis.